The FDA on Thursday granted accelerated approval for tucatinib (Tukysa) when given with trastuzumab to treat adults with RAS wild-type, metastatic or unresectable HER2-positive colorectal cancer (mCRC) that progresses after treatment with specific types of chemotherapy. Approval of this chemotherapy-free combination is based on results from the phase 2 MOUNTAINEER trial (NCT03043313), which found an […]
Phase 2 Dose Study of CTX-009 First Patient with Metastatic Colorectal Cancer
After early preclinical and clinical studies showed promising data with CTX-009 therapy, a phase 2 study of the agent dosed its first patient with metastatic colorectal cancer. The first patient was given in the phase 2 study (NCT05513742) of CTX-009 given in the third- or fourth-line setting for patients with metastatic colorectal cancer, according to […]